

Express Mail Lab I No.: EV 312717176
Date of Deposit: December 18, 2003

Page 1 of 1
Attorney Docket No.: 18217-515

Please type a plus sign (+) in this box



PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO		Application Number	10/602,325
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date of U.S. Nat'l Appl.	June 23, 2003
		First Named Inventor	Chaplin
		Group Art Unit	1645
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	18217-515

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)			Date of Publication	Translation Yes No
BK	B1	WO 01/74360	ASTRAZENECA AB			10/11/01	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS							
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.					
	C1	Dowlati, et al., "A Phase I Pharmacokinetic and Translational Study of the Novel Vascular Targeting Agent Combretastatin A-4 Phosphate on a Single-Dose Intravenous Schedule in Patients with Advanced Cancer", <i>Cancer Res.</i> , 62:3408-3416 (2002)					
	C2	Honess, et al., "Comparison of Strategies to Overcome the Hypertensive Effect of Combretastatin-A-4 Phosphate in a Rat Model", <i>British J. Cancer</i> , 86(Suppl. I):S118-S119 (2002)					
	C3	Prise, et al., "The Vascular Response of Tumor and Normal Tissues in the Rat to the Vascular Targeting Agent, Combretastatin A-4-Phosphate, at Clinically Relevant Doses", <i>Int'l J. Oncology</i> , 21:717-726 (2002).					
V	C4	Tozer, et al., "Combretastatin A-4 Phosphate as a Tumor Vascular-Targeting Agent: Early Effects in Tumors and Normal Tissues", <i>Cancer Res.</i> , 59:1626-1634 (1999).					

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature	/Brian-Yong Kwon/	Date Considered	03/03/2007
--------------------	-------------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.